Abionic SA

Abionic's CAPSULE PSP Receives FDA Approval for Early Sepsis Detection

- Abionic's CAPSULE PSP, an innovative test for early sepsis detection, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). - The CAPSULE PSP test measures Pancreatic Stone Protein (PSP), a biomarker that rises in response to infections and inflammation, enabling earlier sepsis detection. - Fapon has secured exclusive rights to utilize the PSP biomarker for sepsis diagnosis in China through a strategic partnership with Abionic SA and LASCCO SA. - Fapon is developing and commercializing PSP on its chemiluminescent immunoassay (CLIA) analyzer for the Chinese market, leveraging the FDA approval and strategic collaboration.